SCHEMBL2932479

SCHEMBL2932479

CC(C)C[CH]NC(=O)[C@@H](NC(=O)c1cccc(-c2cccs2)n1)[C@@H](C)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.50
CTSG P08311 1/20 0.50
CYP3A4 P08684 1/20 0.50
PSMB1 P20618 1/20 0.50
CMA1 P23946 1/20 0.50
PSMB8 P28062 1/20 0.50
PSMB9 P28065 1/20 0.50
PSMB5 P28074 1/20 0.50
PSMB10 P40306 1/20 0.50
PSMB2 P49721 1/20 0.50
CNR2 P34972 5/20 0.39
SCN9A Q15858 2/20 0.39
NPC1 O15118 3/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 5/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL608032 0.84 ELANE (0.67) ELANECTSGCYP3A4PSMB1CMA1
SCHEMBL2932488 0.83 ELANE (0.51) ELANECTSGCYP3A4PSMB1CMA1
SCHEMBL2934066 0.82 PSMB5 (0.74) ELANECTSGCYP3A4PSMB1CMA1
SCHEMBL8256787 0.82 PSMB5 (0.74) ELANECTSGCYP3A4PSMB1CMA1
SCHEMBL2933395 0.80 CYP3A4 (0.42) ELANECTSGCYP3A4PSMB1CMA1
SCHEMBL2932701 0.77 HCK (0.39) NPC1RAB9ASMN1; SMN2CAMK2D
SCHEMBL2928270 0.76 ELANE (0.43) ELANECTSGCYP3A4PSMB1CMA1
SCHEMBL2934925 0.76 KDM4E (0.47) ELANECTSGCYP3A4PSMB1CMA1
SCHEMBL2926118 0.75 CCR1 (0.47) ELANECTSGCYP3A4PSMB1CMA1
SCHEMBL2934058 0.75 CYP1A2 (0.43) CYP3A4NPC1RAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US claimed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP claimed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US claimed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US claimed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189806-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 ELANE 1737/4885CTSG 779/4885CYP3A4 4017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.